Stock listing
NASDAQ:MBIO Mustang Bio, Inc. Stock
Home listing (NASDAQ) of Mustang Bio, Inc.
Follow Mustang Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MBIO
$0.354 USD -0.026 (-6.8%)
Close on Nov 20, 2026
- Day range
- $0.354 – $0.379 USDNov 20, 2026
- Volume
- 84,286 sharesNov 20, 2026
- Market cap
- $2.38M USDAt the close on Nov 20, 2026 · price × 6.73M shares outstanding
- 52-week range
- $0.350 – $1.430 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $14,807 USDMedian day 25,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MBIO · Home | $0.354 USD | -0.026 (-6.8%) | 84,286 | $0.379 | $0.379 | $0.354 | $0.380 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.354 | -0.026 | -6.8% | $0.379 | $0.379 | $0.354 | 84,286 | |
| $0.380 | -0.010 | -2.6% | $0.390 | $0.396 | $0.380 | 7,890 | |
| $0.390 | -0.005 | -1.2% | $0.388 | $0.405 | $0.385 | 9,350 | |
| $0.395 | -0.027 | -6.3% | $0.417 | $0.421 | $0.388 | 30,251 | |
| $0.421 | -0.043 | -9.3% | $0.437 | $0.447 | $0.416 | 19,408 | |
| $0.464 | +0.037 | +8.6% | $0.445 | $0.479 | $0.420 | 52,971 | |
| $0.428 | -0.023 | -5.1% | $0.454 | $0.454 | $0.409 | 28,203 | |
| $0.451 | +0.059 | +15.1% | $0.410 | $0.489 | $0.389 | 211,165 | |
| $0.391 | -0.003 | -0.8% | $0.398 | $0.405 | $0.391 | 18,528 | |
| $0.395 | +0.001 | +0.2% | $0.400 | $0.406 | $0.390 | 20,061 | |
| $0.394 | -0.020 | -4.8% | $0.419 | $0.419 | $0.380 | 30,157 | |
| $0.414 | +0.004 | +1.1% | $0.413 | $0.418 | $0.413 | 3,790 | |
| $0.409 | -0.006 | -1.3% | $0.414 | $0.415 | $0.403 | 14,424 | |
| $0.415 | +0.015 | +3.7% | $0.401 | $0.426 | $0.400 | 34,153 | |
| $0.400 | +0.008 | +1.9% | $0.393 | $0.427 | $0.390 | 48,267 | |
| $0.393 | +0.032 | +9.0% | $0.385 | $0.405 | $0.370 | 44,654 | |
| $0.360 | +0.001 | +0.2% | $0.352 | $0.378 | $0.351 | 24,835 | |
| $0.360 | -0.001 | -0.2% | $0.357 | $0.385 | $0.350 | 25,451 | |
| $0.360 | -0.010 | -2.7% | $0.373 | $0.381 | $0.360 | 10,244 | |
| $0.370 | +0.001 | +0.3% | $0.390 | $0.391 | $0.362 | 17,700 | |
| $0.369 | -0.014 | -3.7% | $0.386 | $0.402 | $0.369 | 29,200 | |
| $0.383 | +0.003 | +0.8% | $0.388 | $0.401 | $0.370 | 28,600 | |
| $0.380 | +0.007 | +1.9% | $0.370 | $0.388 | $0.370 | 10,200 | |
| $0.373 | -0.003 | -0.8% | $0.372 | $0.385 | $0.371 | 9,100 | |
| $0.376 | -0.010 | -2.6% | $0.402 | $0.419 | $0.371 | 30,000 | |
| $0.386 | +0.016 | +4.3% | $0.370 | $0.392 | $0.370 | 31,500 | |
| $0.370 | -0.007 | -1.9% | $0.380 | $0.427 | $0.370 | 159,800 | |
| $0.377 | -0.035 | -8.5% | $0.394 | $0.396 | $0.375 | 30,000 | |
| $0.412 | +0.012 | +3.0% | $0.410 | $0.438 | $0.381 | 54,400 | |
| $0.400 | -0.017 | -4.1% | $0.434 | $0.434 | $0.380 | 97,100 | |
| $0.417 | -0.033 | -7.3% | $0.449 | $0.449 | $0.410 | 101,100 | |
| $0.450 | -0.010 | -2.2% | $0.456 | $0.460 | $0.450 | 17,200 | |
| $0.460 | 0.000 | 0.0% | $0.460 | $0.470 | $0.455 | 43,300 | |
| $0.460 | -0.011 | -2.3% | $0.460 | $0.466 | $0.460 | 16,600 | |
| $0.471 | +0.004 | +0.9% | $0.467 | $0.480 | $0.460 | 33,400 | |
| $0.467 | +0.004 | +0.9% | $0.468 | $0.468 | $0.459 | 16,100 | |
| $0.463 | -0.017 | -3.5% | $0.471 | $0.475 | $0.458 | 28,600 | |
| $0.480 | -0.027 | -5.3% | $0.503 | $0.507 | $0.470 | 49,200 | |
| $0.507 | -0.013 | -2.5% | $0.511 | $0.520 | $0.504 | 12,100 | |
| $0.520 | -0.006 | -1.1% | $0.525 | $0.525 | $0.520 | 5,100 | |
| $0.526 | +0.015 | +2.9% | $0.540 | $0.544 | $0.501 | 39,000 | |
| $0.511 | -0.020 | -3.8% | $0.487 | $0.550 | $0.487 | 24,100 | |
| $0.531 | -0.019 | -3.5% | $0.541 | $0.554 | $0.531 | 18,900 | |
| $0.550 | +0.010 | +1.9% | $0.530 | $0.558 | $0.530 | 42,300 | |
| $0.540 | +0.050 | +10.2% | $0.490 | $0.540 | $0.490 | 52,500 | |
| $0.490 | -0.010 | -2.0% | $0.511 | $0.511 | $0.485 | 26,600 | |
| $0.500 | -0.004 | -0.8% | $0.513 | $0.513 | $0.466 | 41,800 | |
| $0.504 | -0.006 | -1.2% | $0.545 | $0.545 | $0.504 | 41,700 | |
| $0.510 | +0.003 | +0.6% | $0.539 | $0.539 | $0.507 | 20,500 | |
| $0.507 | -0.013 | -2.5% | $0.532 | $0.550 | $0.507 | 25,900 | |
| $0.520 | -0.008 | -1.5% | $0.540 | $0.540 | $0.520 | 20,600 | |
| $0.528 | -0.013 | -2.4% | $0.552 | $0.552 | $0.524 | 8,900 | |
| $0.541 | -0.002 | -0.4% | $0.540 | $0.555 | $0.533 | 22,500 | |
| $0.543 | -0.017 | -3.0% | $0.553 | $0.558 | $0.532 | 37,400 | |
| $0.560 | +0.017 | +3.1% | $0.543 | $0.561 | $0.543 | 29,900 | |
| $0.543 | -0.005 | -0.9% | $0.550 | $0.550 | $0.541 | 11,600 | |
| $0.548 | +0.010 | +1.9% | $0.540 | $0.549 | $0.537 | 18,100 | |
| $0.538 | 0.000 | 0.0% | $0.538 | $0.540 | $0.533 | 9,100 | |
| $0.538 | -0.012 | -2.2% | $0.550 | $0.550 | $0.530 | 20,300 | |
| $0.550 | -0.010 | -1.8% | $0.560 | $0.560 | $0.548 | 33,200 | |
| $0.560 | +0.008 | +1.4% | $0.545 | $0.568 | $0.545 | 15,800 | |
| $0.552 | +0.001 | +0.2% | $0.551 | $0.577 | $0.550 | 6,300 | |
| $0.551 | -0.028 | -4.8% | $0.570 | $0.578 | $0.550 | 31,800 | |
| $0.579 | +0.006 | +1.0% | $0.573 | $0.579 | $0.570 | 6,500 | |
| $0.573 | -0.001 | -0.2% | $0.560 | $0.573 | $0.560 | 14,200 |
Splits
2 splits since 2023 · NASDAQ:MBIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:MBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Latest news
Mustang Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 123 in all · newest Jul 7, 2025 · oldest 2019
- Decks
- 4 decks · latest February 2024
Where Mustang Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MBIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:MBIO | BOATS | United States | USD |
Valuation
Price/book 0.4× against a median of 0.4×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$11.89M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| Median of the others | US$2.40M | US$1.93M | 0.7× | 12.2× | 0.4× | −301.9% | 0.1× | 1.30 |
Team and board
Officers
| Officer | Role |
|---|---|
| Manuel Litchman | President, Chief Executive Officer and Director |
| Greg Furrow | Chief Quality Officer |
Board
| Director | Role |
|---|---|
| Michael S. Weiss | Chairman of the Board of Directors |
| Adam J. Chill | Director |
| David Jin | Director |
| Lindsay A. Rosenwald | Director |
| Manuel Litchman | President, Chief Executive Officer and Director |
| Michael J. Zelefsky | Director |
| Neil Herskowitz | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −15.0% |
| Q2 2026 | Aug 5, 2026 | −3.2% |
| Q1 2026 | May 29, 2026 | +21.3% |
| Q4 2025 | Mar 10, 2026 | +7.7% |
| Q3 2025 | Nov 7, 2025 | −2.4% |
| Q2 2025 | Aug 8, 2025 | +15.8% |
| Q1 2025 | May 13, 2025 · After close | 0.0% |
| Q4 2024 | Mar 28, 2025 · Before open | −6.3% |
| Q3 2024 | Nov 8, 2024 · After close | +0.8% |
| Q2 2024 | Aug 13, 2024 · After close | −7.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | +8.5% |
| Q4 2023 | Mar 11, 2024 · After close | −8.6% |
| Q3 2023 | Nov 14, 2023 · After close | +2.9% |
| Q2 2023 | Aug 14, 2023 · After close | −5.7% |
| Q1 2023 | May 12, 2023 · After close | −6.7% |
| Q4 2022 | Mar 29, 2023 · After close | +6.3% |
| Q3 2022 | Nov 14, 2022 · After close | −2.3% |
| Q2 2022 | Aug 11, 2022 · After close | +1.6% |
| Q1 2022 | May 12, 2022 · After close | +5.6% |
| Q4 2021 | Mar 23, 2022 · After close | +22.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2024) | Investor deck | 47 slides | February 2024 |
| Investor Presentation (June 2017) | Investor deck | 27 slides | Jun 9, 2017 |
| Investor Presentation (April 2016) | Investor deck | 20 slides | April 2016 |
| Investor Presentation (March 2016) | Investor deck | 20 slides | March 2016 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or common stock equivalents) with Series C-1 and Series C-2 warrants Closed: US$8M raised · US$3.01 a share · Warrants at US$3.01 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate and other purposes | Feb 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 41.0K | 823.0K | 2.23M | 3.03M | 2.31M | 1.78M | 1.37M | 630.0K | 2.00K | 0 |
| Gross profit | -41.0K | -823.0K | -2.23M | -3.03M | -2.31M | -1.78M | -1.37M | -630.0K | -2.00K | 0 |
| Research and development | 1.52M | 7.56M | 40.5M | 62.5M | 49.9M | 37.2M | 30.0M | 2.10M | 100.0K | 2.00M |
| Selling, general and administrative | 3.95M | 4.13M | 9.69M | 12.2M | 11.0M | 9.51M | 9.57M | 6.76M | 11.4M | 2.82M |
| Operating income | -2.43M | -16.2M | -49.3M | -76.2M | -66.7M | -56.8M | -45.9M | -31.2M | -31.8M | -11.4M |
| Depreciation and amortization | 34.0K | 671.0K | 1.86M | 2.72M | 2.17M | 1.68M | 1.26M | 630.0K | 2.00K | 0 |
| EBITDA | -2.40M | -15.6M | -47.4M | -73.4M | -64.6M | -55.1M | -44.6M | -30.6M | -31.8M | -11.4M |
| Interest expense | 5.00K | 4.11M | 3.36M | 15.0K | 3.92M | 1.77M | 8.00K | 8.00K | 895.0K | |
| Income before tax | -1.92M | -15.8M | -51.6M | -77.5M | -66.4M | -60.0M | -46.4M | -30.7M | -31.3M | -12.7M |
| Income tax | 27.0K | -15.8M | 1.37M | -2.29M | 2.13M | 1.77M | 569.0K | 505.0K | 23.9M | |
| Net income | -1.92M | -15.8M | -51.6M | -77.5M | -66.4M | -60.0M | -46.4M | -30.7M | -31.3M | -12.7M |
| Earnings per share, basic | -0.39 | -38.57 | -299.95 | -10.09 | -0.76 | -1.14 | -1.29 | -1.14 | -1.24 | -1.15 |
| Earnings per share, diluted | -0.39 | -38.57 | -299.95 | -10.09 | -0.76 | -1.14 | -1.29 | -1.14 | -1.24 | -1.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.3M | 6.84M | 6.23M | 75.7M | 109.6M | 97.8M | 61.4M | 16.5M | 35.5M | 27.5M |
| Short-term investments | 0 | 17.6M | 26.0M | 0 | ||||||
| Receivables | 217.0K | 402.0K | 3.88M | 299.0K | 50.0K | 15.0K | 19.0K | 37.0K | 106.0K | |
| Inventory | 0 | 0 | ||||||||
| Current assets | 17.6M | 8.61M | 11.3M | 78.9M | 111.7M | 99.5M | 63.1M | 35.1M | 61.4M | 27.5M |
| Property, plant and equipment | 0 | 371.0K | 3.25M | 8.44M | 11.1M | 8.03M | 7.94M | 6.86M | 1.38M | 0 |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 17.6M | 9.31M | 17.7M | 92.4M | 125.2M | 109.9M | 73.4M | 42.8M | 63.5M | 27.5M |
| Accounts payable | 3.51M | 7.46M | 6.32M | 6.83M | 3.51M | 3.52M | 1.88M | 1.39M | 3.47M | 683.0K |
| Current liabilities | 7.91M | 12.6M | 15.4M | 15.1M | 10.8M | 9.52M | 7.77M | 5.62M | 3.61M | 3.22M |
| Long-term debt | 27.4M | 12.2M | 0 | 0 | ||||||
| Total debt | 878.0K | 2.50M | 31.4M | 2.03M | 2.23M | 15.5M | 320.0K | |||
| Total liabilities | 8.06M | 13.2M | 17.6M | 46.1M | 12.8M | 11.5M | 21.8M | 6.36M | 3.66M | 3.22M |
| Shareholders' equity | 9.53M | -3.87M | 123.0K | 46.3M | 112.4M | 98.4M | 51.7M | 36.4M | 59.8M | 24.3M |
| Shares outstanding | 4.91M | 6.13M | 8.60M | 6.90M | 93.6M | 70.9M | 39.4M | 26.6M | 25.2M | 15.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.26M | -11.4M | -49.5M | -65.1M | -53.7M | -37.3M | -33.6M | -19.2M | -12.9M | -4.13M |
| Capital spending | 0 | 0 | -64.0K | -2.71M | -3.99M | -1.93M | -2.35M | -6.87M | -424.0K | -424.0K |
| Free cash flow | -5.26M | -11.4M | -49.5M | -67.8M | -57.7M | -39.2M | -35.9M | -26.1M | -13.4M | -4.13M |
| Cash from investing | 1.17M | 0 | 5.89M | -2.95M | -5.37M | -4.41M | 13.9M | 557.0K | -29.1M | 0 |
| Cash from financing | 14.5M | 11.3M | -26.1M | 34.1M | 70.8M | 78.1M | 65.1M | 181.0K | 50.0M | 31.6M |
| Dividends paid | -273.0K | -611.0K | -477.0K | -320.0K | 0 | |||||
| Share buybacks | 923.0K | 35.2M | 29.5M | 181.0K | 1.68M | 35.0M | ||||
| Change in cash | 10.4M | -145.0K | -69.7M | -34.0M | 11.8M | 36.4M | 45.4M | -18.5M | 7.98M | 27.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Nov 20, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Nov 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 17, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 5, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Dec 3, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Sep 5, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 14, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 4, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| POS EX | Apr 1, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 1, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| DEF 14C | Mar 3, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Feb 27, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 27, 2025 | Acquisition or disposal | SEC |
| PRE 14C | Feb 21, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 21, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 13, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 13, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Feb 7, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 5, 2025 | Offer document | SEC |
| DEF 14C | Jan 22, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Jan 20, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 17, 2025 | Current report | SEC |
| S-1 · Registration statement | Jan 15, 2025 | Offer document | SEC |
| PRE 14C | Jan 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 10, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 3, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Dec 6, 2024 | Meeting notice | SEC |
| 424B3 · Prospectus | Dec 2, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 29, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 25, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 22, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 15, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 25, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 13, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 16, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jul 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 25, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jul 19, 2024 | Offer document | SEC |
| DEF 14C | Jul 10, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 3, 2024 | Acquisition or disposal | SEC |
| 424B5 · Prospectus | Jul 3, 2024 | Offer document | SEC |
| PRE 14C | Jun 28, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 28, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| D | Jun 21, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 21, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 21, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jun 20, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 10, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 6, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 31, 2024 | Offer document | SEC |
| 8-K · Current report | May 21, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | May 13, 2024 | Offer document | SEC |
| 8-K · Current report | May 2, 2024 | Material contract | SEC |
| 424B4 · Prospectus | May 1, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 29, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 29, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 29, 2024 | Results | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 29, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 12, 2024 | Current report | SEC |
| S-1/A · Registration statement, amended | Apr 2, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 29, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Mar 20, 2024 | Other filings | SEC |
| S-1 · Registration statement | Mar 15, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 15, 2024 | Current report | SEC |
| 8-K · Current report | Mar 11, 2024 | Results | SEC |
| 10-K · Annual report | Mar 11, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 14, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 25, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2023 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Dec 18, 2023 | Other filings | SEC |
| S-1 · Registration statement | Dec 11, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| D | Nov 3, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 2, 2023 | Current report | SEC |
| 8-K · Current report | Oct 30, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Oct 30, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 26, 2023 | Current report | SEC |
| 8-K · Current report | Oct 4, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 28, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 23, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 16, 2023 | Current report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Jul 31, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 31, 2023 | Acquisition or disposal | SEC |
| 8-K · Current report | Jul 20, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 23, 2023 | Management or board change | SEC |
| 8-K · Current report | May 22, 2023 | Material contract | SEC |
| 8-K · Current report | May 12, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 20, 2023 | Current report | SEC |
| 424B5 · Prospectus | Apr 14, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 13, 2023 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Apr 6, 2023 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Apr 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 3, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 29, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 29, 2023 | Results | SEC |
| DEF 14C | Mar 13, 2023 | Meeting notice | SEC |
| PRE 14C | Mar 3, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 3, 2023 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 13, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2022 | Material contract | SEC |
| 8-K · Current report | Nov 25, 2022 | Current report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Jul 15, 2022 | Offer document | SEC |
| SC 13G · Big-stake notice | Jul 8, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jul 7, 2022 | Current report | SEC |
| 8-K · Current report | Jun 24, 2022 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jun 7, 2022 | Insider trade | SEC |
| 8-K · Current report | May 31, 2022 | Current report | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2022 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2022 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Apr 19, 2022 | Meeting notice | SEC |
| 8-K · Current report | Mar 23, 2022 | Results | SEC |
| 10-K · Annual report | Mar 23, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2022 | Management or board change | SEC |
| 8-K · Current report | Mar 8, 2022 | Material contract | SEC |
| SC 13G · Big-stake notice | Feb 4, 2022 | Big-stake notice | SEC |
This page holds 200 of 406 filings. Open Filings
Cap table
Built by 6ix from Mustang Bio, Inc.’s releases · as of Feb 10, 2025
- Common shares
- 6,732,121
- Fully diluted
- 6,732,121
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 6,732,121 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.01 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 6,732,121 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael S. Weiss Other companies: Checkpoint Therapeutics Inc (Director · Since at least Sep 9, 2016); Fortress Biotech, Inc. (Executive Vice Chairman, Strategic Development · Since at least Jan 1, 2016); TG Therapeutics, Inc. (Chairman, President, and Chief Executive Officer · Since at least Dec 31, 2015); Avenue Therapeutics, Inc. (Director · Mar 13, 2017 – Aug 7, 2018 · Past); National Holdings Corporation (Director · Sep 12, 2016 – Sep 12, 2016 · Past) | Chairman of the Board of Directors · Since at least Sep 26, 2016 |
| Lindsay A. Rosenwald Other companies: Avenue Therapeutics, Inc. (Director · Since at least Sep 23, 2024); Checkpoint Therapeutics Inc (Director · Since at least May 14, 2024); Journey Medical Corporation (Director · Since at least Mar 22, 2024); Fortress Biotech, Inc. (PRESIDENT, CEO & CHAIRMAN, Director · Since at least Nov 14, 2023) | Director · Since at least Nov 5, 2026 |
| Neil Herskowitz Other companies: Journey Medical Corporation (Director · Since at least Nov 16, 2021); Checkpoint Therapeutics Inc (Director · Since at least Jun 14, 2018); Avenue Therapeutics, Inc. (Director · Since at least Oct 9, 2017); National Holdings Corporation (Director · Feb 12, 2018 – Feb 12, 2018 · Past) | Director · Since at least Jun 14, 2018 |
| Eliot M Lurier Other companies: Marker Therapeutics, Inc. (Interim CFO · Jun 30, 2023 – Jun 30, 2023 · Past); Tenax Therapeutics, Inc. (Interim CFO · Oct 29, 2021 – Oct 29, 2021 · Past); Interleukin Genetics Inc (Chief Financial Officer · Mar 23, 2011 – Oct 22, 2013 · Past) | Interim CFO · Apr 18, 2022 – Apr 18, 2022 · Past |
| David Jin Other companies: Fortress Biotech, Inc. (Chief Financial Officer and Head of Corporate Development · Since at least Aug 16, 2022); Avenue Therapeutics, Inc. (Interim Chief Financial Officer and Chief Operating Officer · Since at least May 11, 2022) | Director · Since at least Oct 23, 2024 |
| Adam J. Chill Other companies: Origo Acquisition Corporation (Director · Dec 12, 2014 – May 20, 2016 · Past) | Director · Since at least Jun 7, 2017 |
| James B Murphy Other companies: Decibel Therapeutics Inc (See Remarks · Oct 7, 2022 – Oct 7, 2022 · Past) | Interim CFO · Jan 19, 2024 – Jan 19, 2024 · Past |
| Greg Furrow | Chief Quality Officer · Since at least Nov 4, 2026 |
| Manuel Litchman | President, Chief Executive Officer and Director · Since at least Apr 24, 2017 |
| Michael J. Zelefsky | Director · Since at least Jul 29, 2022 |
All 11 people
| Person | Seat |
|---|---|
| Peter Carney | See Remarks · Dec 11, 2023 – Dec 11, 2023 · Past |
Log in to ask 6ix AI your own questions about Mustang Bio, Inc.